Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Lonza Group Ltd ( (CH:LONN) ) is now available.
Lonza has nominated veteran pharmaceutical executive Stephen Fry as an independent member of its Board of Directors, with election scheduled for the May 2026 Annual General Meeting. Contingent on shareholder approval, he will also join the People and Governance Committee and the Audit and Compliance Committee, reflecting the company’s focus on strengthening oversight and organizational strategy.
Fry brings more than three decades of international leadership experience from Eli Lilly, where he led large-scale organizational transformation and served as Executive Vice President and Chief Human Resources Officer for 12 years. Lonza’s chairman highlighted that his expertise in governance, succession planning and people strategy is expected to reinforce the group’s performance culture and talent agenda, supporting its ambitions as a leading CDMO to attract and develop high-performing teams worldwide.
The most recent analyst rating on (CH:LONN) stock is a Hold with a CHF481.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.
More about Lonza Group Ltd
Lonza Group AG is a global contract development and manufacturing organization (CDMO) focused on the healthcare industry, partnering with pharma and biotech companies to turn innovative therapies into commercial products. Headquartered in Basel and operating across five continents with about 20,000 employees, the company generated CHF 6.5 billion in sales and CHF 2.1 billion in CORE EBITDA in 2025.
Average Trading Volume: 168,809
Technical Sentiment Signal: Hold
Current Market Cap: CHF33.97B
For detailed information about LONN stock, go to TipRanks’ Stock Analysis page.